

Special Issue

Angiogenesis and Inflammation in Biological Barriers

Message from the Guest Editor

Biological barriers are essential for the integrity and proper function of many vertebrate organs and are critical for the regulation of tissue homeostasis and protection against pathogens or other tissue-damaging agents. BB separate internal and external compartments and are formed by specialized cell types, such as epithelial and endothelial cells, that interface the body and the external environment. Processes such as vascularization, angiogenesis, and inflammation play major roles in the control of the integrity of these barriers. Specialized pro- and anti-angiogenic and inflammatory factors control these processes. The latter includes the inflammasome family. Recent studies have also reported the involvement of new factors that control both angiogenic and inflammatory processes, such as the prokineticin family. Failure in the expression of these factors and/or impaired epithelial–endothelial barrier function are major hallmarks of several barrier-associated pathologies. This Special Issue welcomes original articles and reviews focused on angiogenesis and inflammation in highly vascularized biological barriers.

Guest Editor

Dr. Nadia Alfaidy

Biology and Biotechnology for Health, Biosanté, INSERM U1292, Grenoble, France

Deadline for manuscript submissions

closed (31 January 2021)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/55224

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).